Literature DB >> 25104182

Validation of the dyspnea index in adolescents with exercise-induced paradoxical vocal fold motion.

Vanessa De Guzman1, Catherine L Ballif1, Rie Maurer1, Christopher J Hartnick2, Nikhila Raol2.   

Abstract

IMPORTANCE: Paradoxical vocal fold motion (PVFM) affects almost 1 million adolescents in the United States. However, to date, no disease-specific objective measure exists to assess symptom severity and response to treatment in adolescents with exercise-induced PVFM.
OBJECTIVES: To validate the Dyspnea Index (DI) quality-of-life instrument (previously validated for adults with breathing disorders) in children aged 12 to 18 years with exercise-induced PVFM and to determine the minimum significant DI change corresponding to patient-reported or caregiver-reported improvement or worsening of symptoms. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal study of 56 patients (age range, 12-18 years) diagnosed as having exercise-induced PVFM and their caregivers from February 1, 2013, to September 30, 2013, in an outpatient pediatric otolaryngology office practice.
INTERVENTIONS: The DI was administered to patients and caregivers, with items modified to reflect the perspective of caregivers. MAIN OUTCOMES AND MEASURES: Appropriate DI change was measured to reflect improvement or worsening of symptoms. Test-retest reliability was accomplished by having a subset of patients and caregivers complete the instrument twice within 2 weeks before therapy. Internal consistency was assessed by calculation of Cronbach α. Discriminant validity and convergent validity were determined by comparing DIs with assessment of global change in symptoms.
RESULTS: The patient and caregiver mean (SD) DI changes were -12.9 (9.6) and -14.7 (9.3), respectively (P < .001 for both). Reliability was established by test-retest analysis with an intraclass correlation coefficient of 0.8 and by calculation of Cronbach α = 0.80, demonstrating internal consistency. Discriminant validity was determined by assessing for a significant DI change when patients globally perceived that a change existed after treatment (P < .001). A DI change of 8 or higher (P < .001) correlated with patient-reported significant change. Convergent validity was demonstrated by evaluating for significant DI change when no change was reported following treatment (P < .001). CONCLUSIONS AND RELEVANCE: The DI appears to be a valid and reliable instrument to assess quality of life in exercise-induced pediatric PVFM. A DI change of 8 or higher seems significant. This instrument can serve as an objective tool to assess change in exercise-induced pediatric PVFM following speech therapy.

Entities:  

Mesh:

Year:  2014        PMID: 25104182     DOI: 10.1001/jamaoto.2014.1405

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  4 in total

Review 1.  Exercise induced laryngeal obstruction: a review of diagnosis and management.

Authors:  Savinda Liyanagedera; Robert McLeod; Hassan A Elhassan
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-11       Impact factor: 2.503

2.  Dyspnea Index: An upper airway obstruction instrument; translation and validation in Swedish.

Authors:  Eleftherios Ntouniadakis; Ole Brus; Mathias von Beckerath
Journal:  Clin Otolaryngol       Date:  2021-01-03       Impact factor: 2.597

3.  Exercise-induced Laryngeal Obstruction: Protocol for a Randomized Controlled Treatment Trial.

Authors:  Hege Clemm; Ola D Røksund; Tiina Andersen; John-Helge Heimdal; Tom Karlsen; Magnus Hilland; Zoe Fretheim-Kelly; Karl Ove Hufthammer; Astrid Sandnes; Sigrun Hjelle; Maria Vollsæter; Thomas Halvorsen
Journal:  Front Pediatr       Date:  2022-02-07       Impact factor: 3.418

Review 4.  Exercise-induced laryngeal obstruction (EILO) in athletes: a narrative review by a subgroup of the IOC Consensus on 'acute respiratory illness in the athlete'.

Authors:  Hege Havstad Clemm; J Tod Olin; Cameron McIntosh; Martin Schwellnus; Nicola Sewry; James H Hull; Thomas Halvorsen
Journal:  Br J Sports Med       Date:  2022-02-22       Impact factor: 18.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.